The purpose of this study is to find the highest dose of the investigational drug BMS-986015 that can be given safely with another investigational drug, BMS-936558, in patients with advanced solid tumors that are no longer responding to standard therapies.
BMS-936558 works by attaching to and blocking a molecule called PD-1. BMS-986015 attaches to and blocks a group of molecules called KIR. PD-1 and KIR are proteins present mainly on immune system cells, and each controls part of the immune system by shutting it down. It is hoped that by binding to and inactivating these proteins, this drug combination can enhance the body’s ability to detect and destroy cancer cells.